Last reviewed · How we verify
Botox®50U
At a glance
| Generic name | Botox®50U |
|---|---|
| Sponsor | CKD Bio Corporation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Botulinum Toxin A in Patients With Posttraumatic Headache (PHASE3)
- Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines (PHASE1)
- Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy (PHASE2)
- A Trial of Pelvic Floor Chemodenervation in Patients Undergoing Physical Therapy for High Tone Pelvic Floor Dysfunction (PHASE4)
- Pharmacodynamic and Safety of MT10107(Botulinum Type A Neurotoxin) in Comparison to BOTOX® (PHASE1)
- Efficacy and Safety Study of MT10109L in the Treatment of Glabella Line(Including a Preliminary Study to Evaluate Safety of MT10109L) (PHASE2, PHASE3)
- Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery (PHASE1, PHASE2)
- Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Botox®50U CI brief — competitive landscape report
- Botox®50U updates RSS · CI watch RSS
- CKD Bio Corporation portfolio CI